We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-14.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$9.59M
AUM Growth
-$434M
Cap. Flow
-$279M
Cap. Flow %
-2,907.54%
Top 10 Hldgs %
47.01%
Holding
85
New
15
Increased
1
Reduced
62
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.17M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.24M
3
BNTX icon
BioNTech
BNTX
+$588K
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$408K
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$180K

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$16.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$16.6M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.2M
4
PTCT icon
PTC Therapeutics
PTCT
+$14.4M
5
AMGN icon
Amgen
AMGN
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Miscellaneous 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDYA icon
26
IDEAYA Biosciences
IDYA
$4.03B
$109K 1.14%
1,501
-107,499
-99% -$1.2M
GMDA
27
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$107K 1.12%
187
-106,813
-100% -$271K
FOLD
28
DELISTED
Amicus Therapeutics
FOLD
$94.6K 0.99%
1,017
-93,583
-99% -$771K
BMRN icon
29
BioMarin Pharmaceuticals
BMRN
$12.6B
$79.7K 0.83%
6,601
-73,055
-92% -$5.82M
ZLAB icon
30
Zai Lab
ZLAB
$3.01B
$79K 0.82%
2,736
-76,222
-97% -$2.69M
GH icon
31
Guardant Health
GH
$22.6B
$74.5K 0.78%
3,005
-71,495
-96% -$3.54M
HCM icon
32
HUTCHMED
HCM
$2.16B
$68K 0.71%
859
-67,141
-99% -$855K
SGEN
33
DELISTED
Seagen Inc. Common Stock
SGEN
$65.6K 0.68%
11,607
-64,593
-85% -$9.31M
ITCI
34
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$63.2K 0.66%
3,603
-47,353
-93% -$2.68M
RCKT icon
35
Rocket Pharmaceuticals
RCKT
$398M
$63K 0.66%
868
-62,132
-99% -$741K
IMVT icon
36
Immunovant
IMVT
$9.05B
$60K 0.63%
233
-59,767
-100% -$258K
IRWD icon
37
Ironwood Pharmaceuticals
IRWD
$702M
$60K 0.63%
+692
New +$8.15K
GMAB icon
38
Genmab
GMAB
$21B
$57.2K 0.6%
+1,857
New +$60.2K
BCRX icon
39
BioCryst Pharmaceuticals
BCRX
$2.52B
$57K 0.59%
602
-56,398
-99% -$582K
BIIB icon
40
Biogen
BIIB
$32.7B
$52K 0.54%
+10,606
New +$2.17M
ALKS icon
41
Alkermes
ALKS
$8.2B
$51K 0.53%
+1,519
New +$43.6K
ALLO icon
42
Allogene Therapeutics
ALLO
$726M
$50K 0.52%
570
-49,430
-99% -$439K
AVDL
43
DELISTED
Avadel Pharmaceuticals
AVDL
$50K 0.52%
122
-49,878
-100% -$205K
ILMN icon
44
Illumina
ILMN
$34.4B
$48K 0.5%
9,098
-40,246
-82% -$10.3M
IONS icon
45
Ionis Pharmaceuticals
IONS
$10.4B
$46.1K 0.48%
1,703
-152,385
-99% -$5.75M
KRYS icon
46
Krystal Biotech
KRYS
$10.6B
$45K 0.47%
2,955
-42,045
-93% -$2.62M
AMGN icon
47
Amgen
AMGN
$236B
$40.7K 0.43%
9,915
-56,831
-85% -$13.9M
INSM icon
48
Insmed
INSM
$26.5B
$40.1K 0.42%
791
-39,309
-98% -$824K
ALNY icon
49
Alnylam Pharmaceuticals
ALNY
$31.6B
$38K 0.4%
5,542
-32,458
-85% -$4.6M
DNLI icon
50
Denali Therapeutics
DNLI
$3.94B
$38K 0.4%
1,118
-36,882
-97% -$966K
1
2
3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2022 Portfolio in Review

As of Q2 2022, International Biotechnology Trust held 85 positions worth $9.59M, down 98% from $443M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $279M in Q2 2022, closing 7 positions and reducing 62 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $52K.

  • International Biotechnology Trust's largest Q2 2022 buy was Biogen: 10,606 shares worth $52K.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2022, an estimated $1.24M increase.
  • International Biotechnology Trust's biggest Q2 2022 reduction was Incyte, cutting an estimated $16.7M.
  • International Biotechnology Trust fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $9.29M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $9.59M portfolio in Q2 2022.
  • International Biotechnology Trust opened 15 new positions and closed 7 in Q2 2022.
  • International Biotechnology Trust's portfolio value fell 98% quarter-over-quarter to $9.59M.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.